Accelerating endothelialization of coronary stents by capturing circulating endothelial progenitor cells

Interventional Cardiology

Volumn 4, Issue 2, 2012, Pages 169-181

  Yazdani, Saami K ^a   Nakano, Masataka ^a   Otsuka, Fumiyuki ^a   Kolodgie, Frank D ^a   Virmani, Renu ^a  

^a CVPATH INSTITUTE   (United States)

Author keywords

coronary stent; endothelial progenitor cell; endothelialization; late stent thrombosis

Indexed keywords

CD34 ANTIBODY; CYTOSTATIC AGENT; CYTOTOXIC AGENT;

BARE METAL STENT; BLOOD VESSEL INJURY; CELL MIGRATION; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; ENDOTHELIAL PROGENITOR CELL; HIGH RISK PATIENT; HUMAN; MEDICAL DEVICE; MEDICAL LITERATURE; PATIENT SAFETY; PRIORITY JOURNAL; REGENERATION; REVIEW; STENT THROMBOSIS; THERAPY EFFECT;

EID: 84859185709     PISSN: 17555302     EISSN: 17555310     Source Type: Journal    
DOI: 10.2217/ica.11.99     Document Type: Review

References (61)

1. Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. N. Engl. J. Med. 331(8), 489-495 (1994).
2. Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N. Engl. J. Med. 331(8), 496-501 (1994).
3. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349(14), 1315-1323 (2003).
4. Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350(3), 221-231 (2004).
5. Farb A, Boam AB. Stent thrombosis redux - the FDA perspective. N. Engl. J. Med. 356(10), 984-987 (2007).
6. Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369(9562), 667-678 (2007).
7. Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48(1), 193-202 (2006). First report of delayed arterial healing in drug-eluting stents at autopsy.
8. Finn AV, Nakazawa G, Joner M et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler. Thromb. Vasc. Biol. 27(7), 1500-1510 (2007).
9. Finn AV, Joner M, Nakazawa G et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115(18), 2435-2441 (2007).
10. van Beusekom HM, Sorop O, van den Heuvel M et al. Endothelial function rather than endothelial restoration is altered in paclitaxel-as compared to bare metal-, sirolimus and tacrolimus-eluting stents. EuroIntervention 6(1), 117-125 (2010).
11. Joner M, Nakazawa G, Finn AV et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J. Am. Coll. Cardiol. 52(5), 333-342 (2008).
12. Mcfadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364(9444), 1519-1521 (2004).
13. Moreno R, Fernandez C, Hernandez R et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J. Am. Coll. Cardiol. 45(6), 954-959 (2005).
14. Farb A, Sangiorgi G, Carter AJ et al. Pathology of acute and chronic coronary stenting in humans. Circulation 99(1), 44-52 (1999).
15. Carter AJ, Laird JR, Farb A, Kufs W, Wortham DC, Virmani R. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J. Am. Coll. Cardiol. 24(5), 1398-1405 (1994).
16. Haudenschild CC, Schwartz SM. Endothelial regeneration. II. Restitution of endothelial continuity. Lab. Invest. 41(5), 407-418 (1979).
17. Tanaka H, Suzuki A, Schwartz D, Sukhova G, Libby P. Activation of smooth muscle and endothelial cells following balloon injury. Ann. NY Acad. Sci. 748, 526-529 (1995).
18. Newby AC, Southgate KM, Assender JW. Inhibition of vascular smooth muscle cell proliferation by endothelium-dependent vasodilators. Herz 17(5), 291-299 (1992).
19. Dubey RK, Jackson EK, Luscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin 1 receptors. J. Clin. Invest. 96(1), 141-149 (1995).
20. Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85(3), 221-228 (1999). First to demonstrate the role of endothelial progenitor cells in vascular repair.
21. de Val S. Key transcriptional regulators of early vascular development. Arterioscler. Thromb. Vasc. Biol. 31(7), 1469-1475 (2011).
22. Vogeli KM, Jin SW, Martin GR, Stainier DY. A common progenitor for haematopoietic and endothelial lineages in the zebrafish gastrula. Nature 443(7109), 337-339 (2006).
23. Kutryk M, Kuliszewski M. In vivo endothelial progenitor cell seeding for the accelerated endothelialization of endovascular devices. Am. J. Cardiol. 92(6), 94L (2003).
24. + cells in vitro and ex vivo.
25. van Beusekom HM, Ertas G, Sorop O, Serruys PW, van der Giessen WJ. The genous endothelial progenitor cell capture stent accelerates stent re-endothelialization but does not affect intimal hyperplasia in porcine coronary arteries. Catheter. Cardiovasc. Interv. 79(2), 231-242 (2012).
26. Granada JF, Inami S, Aboodi MS et al. Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. Circ. Cardiovasc. Interv. 3(3), 257-266 (2010).
27. Nakazawa G, Granada JF, Alviar CL et al. Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc. Interv. 3(1), 68-75 (2010).
28. Aoki J, Serruys PW, van Beusekom H et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (healthy endothelial accelerated lining inhibits neointimal growth-first in man) registry. J. Am. Coll. Cardiol. 45(10), 1574-1579 (2005). First-in-man clinical results of the Genous stent.
29. Duckers HJ, Soullie T, den Heijer P et al. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent). EuroIntervention 3(3), 350-358 (2007).
30. Duckers HJ, Silber S, de Winter R et al. Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the Healing II trial: evaluation of an endothelial progenitor cell capturing stent. EuroIntervention 3(1), 67-75 (2007).
31. den Dekker WK, Houtgraaf JH, Onuma Y et al. Final results of the HEALING IIB trial to evaluate a bio-engineered CD34 antibody coated stent (Genous stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients. Atherosclerosis 219(1), 245-252 (2011).
32. Silber S, Damman P, Klomp M et al. Clinical results after coronary stenting with the Genous bio-engineered R stent: 12month outcomes of the eHEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry. EuroIntervention 6(7), 819-825 (2011). Largest clinical study to date showing good clinical results of the Genous stent with low incidence of repeat revascularization and stent thrombosis.
33. Damman P, Klomp M, Silber S et al. Duration of dual antiplatelet therapy and outcomes after coronary stenting with the Genous bio-engineered R stent in patients from the e-HEALING registry. Catheter. Cardiovasc. Interv. 79(2), 243-252 (2012).
34. Damman P, Iniguez A, Klomp M et al. Coronary stenting with the Genous™ bio-engineered R stent™ in elderly patients. Circ. J. 75(11), 2590-2597 (2011).
35. Damman P, Klomp M, Beijk MA et al. Twelve-month outcomes after coronary stenting with the Genous bio-engineered R stent in diabetic patients from the eHEALING registry. J. Interv. Cardiol. 24(4), 285-294 (2011).
36. Wohrle J, Birkemeyer R, Markovic S et al. Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease. Heart 97(16), 1338-1342 (2011).
37. Azzarelli S, Galassi AR, Grosso G et al. Clinical and angiographic outcomes in elderly patients treated with endothelial progenitor cell capture coronary stents: results from a prospective single-center registry. J. Invasive Cardiol. 22(12), 594-598 (2010).
38. Miglionico M, Patti G, D'Ambrosio A, Di Sciascio G. Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: a prospective single-center registry in high-risk patients. Catheter. Cardiovasc. Interv. 71(5), 600-604 (2008).
39. Low AF, Lee CH, Teo SG et al. Effectiveness and safety of the Genous endothelial progenitor cell-capture stent in acute ST elevation myocardial infarction. Am. J. Cardiol. 108(2), 202-205 (2011).
40. Beijk MA, Klomp M, Verouden NJ et al. Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. Eur. Heart J. 31(9), 1055-1064 (2010).
41. Beijk MA, Klomp M, van Geloven N et al. Two-year follow-up of the Genous endothelial progenitor cell capturing stent versus the taxus liberte stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study. Catheter. Cardiovasc. Interv. 78(2), 189-195 (2011).
42. Klomp M, Beijk MA, Varma C et al. 1 year outcome of TRIAS HR (TRI-stent adjudication study-high risk of restenosis) a multicenter, randomized trial comparing Genous endothelial progenitor cell capturing stents with drug-eluting stents. JACC Cardiovasc. Interv. 4(8), 896-904 (2011).
43. Co M, Tay E, Lee CH et al. Use of endothelial progenitor cell capture stent (Genous bio-engineered R stent) during primary percutaneous coronary intervention in acute myocardial infarction: intermediate- to long-term clinical follow-up. Am. Heart J. 155(1), 128-132 (2008).
44. Chong E, Poh KK, Liang S et al. Two-year clinical registry follow-up of endothelial progenitor cell capture stent versus sirolimus-eluting bioabsorbable polymer-coated stent versus bare metal stents in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction. J. Interv. Cardiol. 23(2), 101-108 (2010).
45. Beijk MA, Klomp M, Koch KT et al. One-year clinical outcome after provisional T-stenting for bifurcation lesions with the endothelial progenitor cell capturing stent compared with the bare-metal stent. Atherosclerosis 213(2), 525-531 (2010).
46. Lee YP, Tay E, Lee CH et al. Endothelial progenitor cell capture stent implantation in patients with ST segment elevation acute myocardial infarction: one year follow-up. EuroIntervention 5(6), 698-702 (2010).
47. Bystron M, Cervinka P, Spacek R et al. Randomized comparison of endothelial progenitor cells capture stent versus cobalt-chromium stent for treatment of ST elevation myocardial infarction. Six-month clinical, angiographic, and IVUS follow-up. Catheter. Cardiovasc. Interv. 76(5), 627-631 (2010).
48. Klomp M, Beijk MA, Damman P et al. Three-year clinical follow-up of an unselected patient population treated with the Genous endothelial progenitor cell capturing stent. J. Interv. Cardiol. 24(5), 442-449 (2011).
49. Tillman BW, Yazdani SK, Geary RL, Corriere MA, Atala A, Yoo JJ. Efficient recovery of endothelial progenitors for clinical translation. Tissue Eng. Part C Methods 15(2), 213-221 (2009).
50. Yazdani SK, Tillman BW, Berry JL, Soker S, Geary RL. The fate of an endothelium layer after preconditioning. J. Vasc. Surg. 51(1), 174-183 (2010).
51. Walter DH, Rittig K, Bahlmann FH et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105(25), 3017-3024 (2002).
52. Walter DH, Cejna M, Diaz-Sandoval L et al. Local gene transfer of phVEGF2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation 110(1), 36-45 (2004).
53. Plouffe BD, Kniazeva T, Mayer JE Jr, Murthy SK, Sales VL. Development of microfluidics as endothelial progenitor cell capture technology for cardiovascular tissue engineering and diagnostic medicine. FASEB J. 23(10), 3309-3314 (2009).
54. + cells identifies a population of functional endothelial precursors. Blood 95(3), 952-958 (2000).
55. + cells after immobilization on activated platelets. Arterioscler. Thromb. Vasc. Biol. 31(2), 408-415 (2011).
56. Samaroo HD, Lu J, Webster TJ. Enhanced endothelial cell density on NiTi surfaces with sub-micron to nanometer roughness. Int. J. Nanomed. 3(1), 75-82 (2008).
57. Blindt R, Vogt F, Astafieva I et al. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J. Am. Coll. Cardiol. 47(9), 1786-1795 (2006).
58. Martin-Yuste V, Brugaletta S, Ferreira-Gonzalez I et al. Endothelial progenitor cell capturing stent and short dual antiplatelet therapy in patients on chronic anti-vitamin K regimen undergoing percutaneous coronary interventions: long-term outcomes of a single centre registry. EuroIntervention 6(7), 831-837 (2011).
59. Scacciatella P, Meliga E, D'Amico M et al. Percutaneous coronary interventions with an endothelial progenitor cell capture stent (EPC) for high risk patients with no option for drug eluting stents: long term clinical outcomes of a single centre registry. EuroIntervention 6(7), 826-830 (2011).
60. Klomp M, Damman P, Beijk MA et al. Applying the National Institute for Clinical Excellence criteria to patients treated with the Genous™ Bio-engineered R stent™: a sub-study of the eHEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry. Heart Vessels doi:10.1007/s00380-011-0167-8 (2011) (Epub ahead of print).
61. Klomp M, Beijk MA, Tijssen JG, de Winter RJ. One-year clinical outcome in an unselected patient population treated with the Genous endothelial progenitor cell capturing stent. Catheter. Cardiovasc. Interv. 77(6), 809-817 (2011).